Cancer-fighting virus shows promise in early clinical trial

July 8, 2007

A virus that has been specifically designed by scientists to be safe to normal tissue but deadly to cancer is showing early promise in a preliminary study, researchers said at the ESMO Conference Lugano (ECLU), Switzerland.

The virus, called NV1020, is a type of herpes simplex virus modified so that it selectively replicates in virus cells, killing them in the process.

“It doesn’t replicate in normal, healthy cells, so our hope is that it will help fight cancers without causing side-effects in the rest of the body,” said Dr. Axel Mescheder, VP Clinical Research & Development, from the Munich-based biotech company MediGene. The study is conducted in seven leading US-cancer centers, with Dr. Tony Reid from the University of California in San Diego, CA as Principal Investigator. Dr. Mescheder presented preliminary safety and efficacy results and a case report from this ongoing clinical trial in patients with colorectal cancer metastatic to the liver at the meeting.

Dr. Mescheder’s poster presentation described the case of a patient whose cancer had spread to 10 different places around the liver and four in the lungs. He was given the virus treatment in four weekly infusions direct into blood stream, followed by two cycles of approved chemotherapy.

Six months after treatment, scans showed the liver masses had nearly disappeared. “The reduction in the tumor masses was really impressive in this patient,” Dr. Mescheder said. “The hepatic masses almost disappeared.”

The patient survived for 12 months after treatment.

“In the current study, the scientists are testing the treatment in patients with colorectal cancer that have not responded to chemotherapy and where the cancer has spread to the liver,” Dr. Mescheder said. “We are hoping to extend overall survival.”

So far, the findings are looking positive. The treatment seems very tolerable for patients and safe. “The results are really quite encouraging at this early stage,” he said.

Almost 40% of patients with colorectal cancer ultimately die from metastatic disease, where the cancer spreads to other parts of the body. Most of the spreading occurs to the liver and 15% of patients have liver metastases at the time of diagnosis.

The latest human results reported today follow testing in the lab and in animals where the virus was shown to be effective at killing colorectal cancer cells and liver cancers.

Source: European Society for Medical Oncology

Explore further: Cholesterol drug shown to reduce inflammation, other factors in patients

Related Stories

Astrocytes found to keep time for brain, behavior

March 24, 2017

Until recently, work on biological clocks that dictate daily fluctuations in most body functions, including core body temperature and alertness, focused on neurons, those electrically excitable cells that are the divas of ...

Testing for hepatitis C virus remains low among baby boomers

March 8, 2017

A Brief Report appearing in the American Journal of Preventive Medicine looks at testing rates for Hepatitis C virus (HCV) two years after the United States Preventive Services Task Force (USPSTF) recommended it for all baby ...

Recommended for you

Gene research gives new insight into pancreatic cancer

March 29, 2017

One reason pancreatic cancer has a particularly low survival rate is the difficulty in getting drugs to the tumour, but new knowledge of how pancreatic cancer cells invade neighbouring cells could change that.

Study shows how BPA may affect inflammatory breast cancer

March 29, 2017

The chemical bisphenol A, or BPA, appears to aid the survival of inflammatory breast cancer cells, revealing a potential mechanism for how the disease grows, according to a study led by researchers in the Department of Surgery ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.